MYO15B and breast carcinoma: For TN breast cancer, the inclusion of the clinical stage in the epigenetic classifier made it possible to achieve an area under the curve cvAUC = 0.87; 95% CI = 0.86–0.88 with a sensitivity of 0.71 and a specificity of 0.80 for the “TMEM132D, TMEM132C, MYO15B, S” panel.